he American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography now recommend screening of women with a 20-25% or greater lifetime risk of breast cancer. Included in this group are women with a strong family history of breast or ovarian cancer, including those with BRCA mutation and women who received mantle radiation for Hodgkin disease between the ages of 10 and 30 years [1] . The guidelines also state that there are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer. Among these women, tumor recurrence rates after breast conservation therapy (BCT) have historically been estimated at 1-2% per year [2] . With recent improvements in chemotherapy and the use of tamoxifen, recurrence rates at 10 years are now less than 10%, and . Of the 17 women in whom cancer was detected, seven also had benign biopsy results. In total, 18 malignancies were found. One woman had two metachronous cancers. MRI screening resulted in a total of 61 biopsies, with a positive predictive value (PPV) of 39% (95% CI, 27-53%). The malignancies found included 17 carcinomas and one myxoid liposarcoma. Of the 17 cancers, 12 (71%) were invasive, five (29%) were DCIS, and 10 (59%) were minimal breast cancers. Of 17 cancers, 10 were detected by MRI only. The 10 cancers detected by MRI only, versus seven cancers later found by other means, were more likely to be DCIS (4/10 [40%] vs 1/7 [14%]; p = 0.25) or minimal breast cancers (7/10 [70%] vs 3/7 [43%]; p = 0.26).
lifetime risk for these women depends on their age at diagnosis.
In addition to the absolute risk of recurrence, it is important to note that, as with the original breast cancer, the long-term survival of patients with new malignancy after BCT improves with early detection [3] . Detection of treatment failure in these women while it is still subclinical improves relative survival by 27-47% [3] . Conversely, large or nodepositive recurrent tumors are poor prognostic indicators [4] .
Recurrence in the adequately treated breast rarely is discovered sooner than 18-24 months after treatment. Recurrences at the lumpectomy site usually occur within a few years of treatment of the original cancer and likely represent failure to eradicate the entire original tumor. Cancer developing elsewhere in the treated breast is thought to be the result of a new carcinoma and usually is a later event [5] . Mammography's ability to detect recur-
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Breast MRI of Women With History of Breast Cancer rence has been calculated as one third less than its ability to discover the original cancer [6] . The detection of recurrence with mammography is compromised by increased density, architectural distortion, and other posttherapy changes, but it does play a role and is able to detect 25-45% of recurrences. In particular, mammography is better able to detect recurrent tumors that have associated calcifications, because distortion at the surgical site limits evaluation for underlying masses.
Breast MRI has a high sensitivity in the detection of breast cancer. Its sensitivity is reported to be as high as 94-100%. Several studies have already shown the benefit of breast MRI in the detection of tumor recurrence in patients treated with BCT [7] [8] [9] [10] . Breast MRI has a high sensitivity, specificity, and accuracy in differentiating scar from recurrent tumor [11] [12] [13] . To the best of our knowledge, no data are available on the use of breast MRI in screening women with a personal history of breast cancer and no other risk factors. This study was undertaken to determine whether women without indications for MRI screening under current American Cancer Society guidelines and with a personal history of breast cancer would benefit from screening.
Materials and Methods

Patient Population
An institutional review board-approved retrospective review of the records of 1,699 breast MRI scans acquired from 1999 to 2001 was performed. Women with prior breast cancer and without a history that, under current American Cancer Society guidelines, would include them in MRI screening and who met the following criteria were included: no family history of breast cancer, commenced screening during 1999-2001, and had at least 1 year of follow-up with MRI. This yielded 144 women with a history of a prior breast cancer who commenced screening MRI during 1999-2001. These women had a median age of 48 years and a mean age of 49 years (range, 22-73 years). We chose to start reviewing patients from 1999 because this was the first year that we had the capabilities to perform MRI-guided interventions. Choosing this earlier time period allowed us to then follow this cohort of patients for a number of years, from 1999-2001 until 2008. The electronic medical record, including radiology reports and clinical notes, was reviewed to determine which patients developed recurrence. We also reviewed the records of the 1,699 breast MRI examinations performed from 1999 to 2001 to identify women with both a personal and family history of breast cancer who commenced screening MRI examination during that time, so that they could be compared with the group of women with a personal history only.
Breast MRI Technique
MRI was performed on a 1.5-T commercially available system (Sigma, GE Healthcare) using a dedicated surface breast coil. The imaging sequence included a localizing sequence followed by a sagittal fat-suppressed T2-weighted sequence (TR/TE, 4,000/85). A T1-weighted 3D fat-suppressed fast spoiled gradient-echo sequence (17/2.4; flip angle, 35°; bandwidth, 31-25 Hz) was then performed before and three times after a rapid bolus injection of gadopentate dimeglumine (Magnevist, Berlex; 0.1 mmol/L/kg of body weight), delivered through an IV catheter. Image acquisition started after contrast material injection and saline bolus. Images were obtained sagittally for an acquisition time per volumetric acquisition of less than 3 minutes each. Total imaging time per breast, including three contrast-enhanced acquisitions, was approximately 20 minutes. Section thickness was 2-3 mm with no gap using a matrix of 256 × 192 and a field of view of 18-22 cm. Frequency was in the anteroposterior direction. After the examination, the unenhanced images were subtracted from the first contrastenhanced images on a pixel-by-pixel basis.
Breast MRI Interpretation
Breast MRI examinations were interpreted by breast imaging specialists in conjunction with clinical history and other breast imaging studies, including mammography and ultrasound, when available. The individual radiologist classified the lesion detected on MRI on a scale of 1 to 5 adapted from the mammographic BI-RADS classification: 
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BI-RADS I, negative finding; BI-RADS II, benign finding; BI-RADS III, probably benign finding; BI-RADS IV, suspicious finding; and BI-RADS V, highly suggestive of malignancy. Classification was based primarily on lesion morphology. Kinetic features were visually assessed on the three contrast-enhanced image acquisitions, with quantitative kinetic curves generated in specific cases at the discretion of the interpreting radiologist. MRI-detected lesions referred for biopsy included masslike and non-masslike enhancement (linear, clumped, or segmental).
Correlative ultrasound was recommended at the discretion of the interpreting radiologist if it was thought that the lesion might be sonographically evident and amenable to ultrasound-guided biopsy. If it was not seen on ultrasound, then MRI-guided needle localization for surgical excision or MRIguided core needle biopsy was performed.
Data Collection and Analysis
The electronic medical records of these 144 women were reviewed to determine their age, menopausal status, and breast parenchymal density. Family history was determined from the medical records, including radiology reports and patient questionnaires. Prior surgery, radiation, chemotherapy, and tamoxifen use were recorded.
Findings on mammography, ultrasound, and physical examination were reviewed to assess for a correlate to the MRI-detected cancers. Biopsy results were reviewed, including pathology records, to determine the size and stage of breast cancers found and prior breast cancer histology. The MRI screening year in which the cancer was detected was recorded. The number of MRI examinations performed and the number of women who underwent short-term follow-up were also noted. We also determined which patients had preoperative staging with breast MRI for their original cancers.
Data were collected and recorded in spreadsheets (Access and Excel, Microsoft). Statistical analysis was performed with Fisher's exact test using statistical software (Epi Info, Centers for Disease Control and Prevention), with a p value less than 0.05 considered significant. Exact 95% CIs were calculated in accordance with the Geigy scientific tables based on the binomial approximation or exact method. Fisher's exact test was used to compare the distribution of categorical variables between women who had an MRI-detected cancer and those who did not.
Results
These 144 women underwent MRI screening (range, 1-11 MRI examinations) at 1-13 years after their original diagnosis of breast cancer (Table 1) . For those patients who had a cancer detected by MRI, the range of followup with MRI was 1-9 years (mean, 2.7 years; median, 2 years). For those patients who did not have a cancer detected, the range of followup was 1-8 years (mean, 4.2 years; median, 4 years). On the basis of these studies, a total of 61 biopsies were performed, and 18 malignancies were found. One woman had two metachronous cancers. The median number of MRI examinations performed before the cancers were detected was two (range, 1-7), versus five (range, 2-11) in the group who did not develop a cancer. Histologic findings were 17 cancers and one myxoid liposarcoma (Table 2). Of the 17 cancers, 12 (71%) were invasive (11 ductal and one lobular cancer) and five (29%) were ductal carcinoma in situ (DCIS); 10 (59%) were minimal breast cancers defined as DCIS or node-negative breast cancer < 1 cm. The median histologic size of the invasive cancer was 0.8 cm (range, 0.2-4.3 cm). Three (18%) of 17 cancers, representing three (25%) of 12 invasive cancers, had axillary metastases. Prior breast cancer histology had no significant impact on cancer detection rate (Table 3) . There was no significant difference between patients with cancer detected and those with The median age at diagnosis of the original cancer was 47 years (range, 31-71 years) in the group who had an MRI-detected cancer, versus 48 years (range, 22-73 years) in the other group. Eighty-three percent of the women who had an MRI-detected cancer had moderately dense or dense breasts, versus 69% in the other group. The findings were not influenced by menopausal status. Nine (53%) of 17 women in the group who had an MRI-detected cancer were premenopausal, versus 67 (53%) of 127 women in the other group. Forty-one percent of the women who developed a cancer had marked or moderate background enhancement, versus 23% in the other group.
Biopsies were prompted by MRI findings in 44 (31%) of 144 of the women screened, revealing malignancy in 39% of the 44 women who had biopsies. Benign biopsies were performed for 34 (24%) of 144 women screened, with a range of one to five biopsies being performed. MRI screening resulted in a total of 61 biopsies being performed. Biopsy revealed high-risk lesions (including atypical ductal hyperplasia, atypical lobular hyperplasia, lob- ular carcinoma in situ, and papilloma) in six women. In addition to biopsies, short-term follow-up MRI examination was recommended for 58 of the 144 women screened. The biopsy method used for the 18 malignancies was MRI-guided core biopsy in three cases, MRI-guided needle localization in 10 cases, surgical biopsy in three cases, and ultrasoundguided core biopsy in two cases.
We then compared the results of the women with only a personal history of breast cancer (n = 144) with those of the women who also had a family history of breast cancer (n = 136). We found 136 women with both a personal and family history of breast cancer (Table 4) Table  5) . Benign biopsies were performed in 22 (16% [95% CI, 10-23%]) of 136 women screened (range, one to three biopsies per patient) versus 34 (24%) of 144 women with a personal history only (p = 0.1). Similar to patients with a personal history only, cancers were more likely to be found in the early screening rounds; 65% of the cancers were found during the first two screening years. Of the 22 cancers, 14 (64%) were invasive (ductal in 11 cases, lobular in two cases, and mixed in one case), and 8 (36%) were DCIS; 13 (59%) of the 22 breast cancers found were minimal breast cancers.
Discussion
Although the standard of care for screening women with a personal history of breast cancer is mammography, evaluation of the conserved breast is limited. Mammography is better able to detect recurrent tumors that have associated calcifications (Fig. 1) but is less successful in the evaluation of underlying masses in areas of postoperative distortion. Screening mammography is also limited in women with dense breasts (Fig. 2) [14] [15] [16] . Breast MRI has a high sensitivity in the detection of breast cancer and, in particular, a high sensitivity and specificity in differentiating scar from recurrent tumor [11] [12] [13] .
We present the first study, to our knowledge, evaluating the use of breast MRI in screening women with a personal history only of breast cancer. Prior breast cancer histology (p = 0.80), menopausal status (p = 0.80), and breast density (p = 0.31) had no significant im-
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pact on cancer detection rate. A meta-analysis has shown that hormonal therapy reduces local recurrence by 50% [17] , but only 29% of the women who developed cancer in our group had taken hormonal therapy, versus 69% in the other group. Screening with breast MRI detected cancer in 12% (17/144) of women with a history of prior breast cancer and in 39% (17/44) of women who had biopsies prompted by MRI findings. Seventy-two percent (13/18) of malignancies were detected in the first 3 years after initiation of screening, and only 15% of these patients (2/13) had a baseline preoperative MRI. More than half (59%) of the cancers found were minimal breast cancers. DCIS accounted for 29% of the cancers found. In prior reports, DCIS has accounted for 0-57% of cancers detected by MRI screening in high-risk women [15, 16, [18] [19] [20] . The advantage of MRI screening was apparent earlier in the women who did not have a baseline preoperative MRI at the time of original cancer treatment. Thus, although the initial results may have been due to the absence of preoperative MRI, cancers did start to develop further out, and these cancers are difficult to detect with mammography or clinical examination alone. Even if we exclude the three women who developed cancer in the treated breast and did not receive radiation at the time of their initial treatment, on the basis of the fact that this is not standard care, we have a total of 14 women with 15 malignancies. The PPV of a biopsy recommendation in this group is still acceptable at 34% (14/41).
The importance of a personal history of breast cancer as an indication for MRI screening has been suggested by other data. Morris et al. [21] studied MRI screening in a highrisk population and found that the PPV of a biopsy recommendation based on MRI findings in women with a family history of breast cancer (PPV, 32%), was further increased to 50% in women who also had a personal history of breast cancer. Thus, it may not be surprising that the addition of breast MRI in screening women with a personal history of breast cancer, with or without a family history, enables the detection of unsuspected breast cancer and does so with a high PPV (39%). 
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Although Gorechlad et al. [22] argue that the addition of screening MRI in patients after breast-conserving surgery would incur significant cost and would be unlikely to improve overall survival rates, we think that our results show a potential benefit. Gorechlad et al. had an overall recurrence rate of 4%. Ipsilateral recurrences developed in eight patients (1.7%) with a mean diameter of 1.6 cm. Contralateral cancers developed in 11 patients (2.3%) with a mean diameter of 1.5 cm. All of the recurrences were invasive. In contrast, in the present study, we had a cancer detection rate of 12% (17/144). The mean histologic size of the invasive cancers in our group was smaller at 0.8 cm. In addition, 5 (29%) of the cases were DCIS. Earlier detection may therefore be beneficial in allowing the use of less-toxic therapies. Thus, although Gorechlad et al. argue that the cost of screening MRI in terms of patient stress, physician effort, and dollars is high, we see the potential benefit of earlier detection. It is beyond the scope of this study to look at the cost-effectiveness of screening MRI or its impact on survival, but other studies have looked at screening with MRI in women with BRCA1/2 mutations [23] [24] [25] . A study by Taneja et al. [26] found that screening women with MRI was cost effective not only in patients with BRCA1/2 mutations but also among other high-risk women.
In conclusion, this is the largest series to date, to the best of our knowledge on the use of screening with breast MRI in women with a personal history of breast cancer. This screening resulted in the discovery of cancer in 12% of women, with a reasonable biopsy rate and a PPV of 39%. Cancers discovered were those benefiting from early detection, with more than half of the MRI-detected cancers being minimal breast cancers. Although we recognize that screening MRI is costly and does generate many benign biopsies and shortterm follow-ups, we think that it may benefit certain subsets of patients with a personal history of breast cancer. In particular, those who have not had a preoperative MRI at the time of initial cancer diagnosis and those who have not taken hormonal therapy may benefit. We realize that a randomized prospective trial would best determine the effectiveness of MRI screening in women with a personal history of breast cancer and that data from other institutions should be assessed to determine whether our conclusions are supported.
